Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Gastrointestinal 1Breast 1

Conditions

Multiple Myeloma 94Recurrence 17Neoplasms 10Lymphoma, Non-Hodgkin 5Leukemia, Myeloid, Acute 4Neoplasms, Plasma Cell 3Hematologic Neoplasms 3Smoldering Multiple Myeloma 2Plasmacytoma 2Lymphoma, Large B-Cell, Diffuse 2Carcinoma, Non-Small-Cell Lung 2Various Advanced Cancer 1Triple Negative Breast Neoplasms 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Personal Satisfaction 1Patient Satisfaction 1Patient Preference 1Pancreatic Neoplasms 1Myelodysplastic Syndromes 1Microsatellite Unstable Colorectal Cancer 1Lymphoma, T-Cell, Peripheral 1Lymphoma, Mantle-Cell 1Lymphoma, Follicular 1Lymphoma, B-Cell 1Lymphoma 1Immunoglobulin Light-chain Amyloidosis 1Hodgkin Disease 1Hematologic Diseases 1Disease 1Amyloidosis 1

Interventions

Gemcitabine 205130-nm albumin-bound paclitaxel 84Albumin-Bound Paclitaxel 57pembrolizumab 43Fluorouracil 41Leucovorin 34Oxaliplatin 33Capecitabine 25Nivolumab 22Irinotecan 19Bevacizumab 17Paclitaxel 16Cyclophosphamide 15Cetuximab 15Taxes 13Erlotinib Hydrochloride 13Drug Therapy 13Carboplatin 12irinotecan sucrosofate 11Injections 10Cisplatin 9fludarabine 8ALT-803 8spartalizumab 7olaparib 7avelumab 7Pemetrexed 7Docetaxel 7ruxolitinib 6TH 302 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Pancreatic Neoplasms × daratumumab × Clear all
NCT03098550 2021-07-23

A Study to Test the Safety and Effectiveness of Nivolumab Combined With Daratumumab in Patients With Pancreatic, Non-Small Cell Lung or Triple Negative Breast Cancers, That Have Advanced or Have Spread

Bristol-Myers Squibb

Phase 1/2 Completed
105 enrolled 21 charts
BreastGastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Pancreatic Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡